READ-ONLY DIGITIZATION RESULT
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.
CPT Pharmacometrics Syst Pharmacol · 2025-Oct · PMID 40613748
Panel A提取完成待 EXE 对齐验证
PFS
FIGURE 1 Kaplan–Meier plots of PFS (A) and OS (B) stratified by quartiles of ibrutinib AUC τ,ss and efficacy response rates by quartiles of ibrutinib AUC τ,ss (C). Dots show different efficacy endpoint incidences (and 95% CI) at the median ibrutinib AUC t,ss for each ibrutinib AUC t,ss quartile. Dashed lines show the boundaries of the quartiles. Horizontal lines show incidence in placebo arm (black), and the associated 95% CI (gray). [Correction added on 10 July 2025, after first online publication: Resolution for Figure 1 has been updated in this version.]
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 5 | 2026-07-23T18:00:58+00:00 |